Related Experiment Video

Updated: Aug 4, 2025

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

950

Drugging IGF-1R in cancer: New insights and emerging opportunities

Panpan Wang1, Victor Cy Mak1, Lydia Wt Cheung1

  • 1School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.

Genes & Diseases
|April 4, 2023
PubMed

Insights

The insulin-like growth factor type 1 receptor (IGF-1R) drives cancer growth and spread. Therapies targeting IGF-1R, including combination treatments, show promise for improving cancer treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The insulin-like growth factor (IGF) axis is implicated in cancer development and metastasis.
  • The type 1 IGF receptor (IGF-1R) is a critical oncogenic driver across numerous cancer types.

Purpose of the Study:

  • To review IGF-1R aberrations and activation in cancer.
  • To discuss the development and efficacy of anti-IGF-1R therapies.
  • To explore novel strategies for enhancing IGF-1R targeted therapy.

Main Methods:

  • Literature review of pre-clinical and clinical studies on IGF-1R.
  • Analysis of therapeutic agents targeting IGF-1R.
  • Discussion of combination therapy and novel targeting concepts.

Main Results:

  • IGF-1R aberrations and activation mechanisms are common in cancers, supporting therapeutic development.
  • Various agents like antisense oligonucleotides, TKIs, and antibody-drug conjugates are being investigated.
  • Combination therapies targeting IGF-1R and other vulnerabilities show early promise.

Conclusions:

  • Targeting IGF-1R is a validated strategy in oncology.
  • Combination therapies and novel approaches like blocking nuclear translocation may improve efficacy.
  • Further research is needed to overcome challenges and optimize IGF-1R-directed cancer treatments.
Keywords:
CancerCombination therapyIGF-1RMetastasisTargeted therapy

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.4K
Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis09:13

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Published on: January 5, 2024

1.3K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
598